Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Tumor suppressors BTG1 and BTG2: Beyond growth control.

Yuniati L, Scheijen B, van der Meer LT, van Leeuwen FN.

J Cell Physiol. 2018 Oct 23. doi: 10.1002/jcp.27407. [Epub ahead of print] Review.

PMID:
30350856
2.

Multifocal occurrence of extra-abdominal desmoid type fibromatosis - A rare manifestation. A clinicopathological study of 6 sporadic cases and 1 hereditary case.

Bekers EM, van Broekhoven DLM, van Dalen T, Bonenkamp JJ, van der Geest ICM, de Rooy JWJ, van Gorp JM, Creytens DH, de Leng WWJ, Scheijen B, Eijkelenboom A, Flucke U.

Ann Diagn Pathol. 2018 Aug;35:38-41. doi: 10.1016/j.anndiagpath.2018.04.001. Epub 2018 Apr 21.

3.

The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia.

Marke R, van Leeuwen FN, Scheijen B.

Haematologica. 2018 Apr;103(4):565-574. doi: 10.3324/haematol.2017.185603. Epub 2018 Mar 8. Review.

4.

Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.

Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Gerritsen M, van der Meer LT, Williams O, Hoogerbrugge PM, Scheijen B, van Leeuwen FN.

Exp Hematol. 2018 Apr;60:57-62.e3. doi: 10.1016/j.exphem.2018.01.006. Epub 2018 Feb 8.

PMID:
29408281
5.

Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma.

Schreuder MI, van den Brand M, Hebeda KM, Groenen PJTA, van Krieken JH, Scheijen B.

J Hematop. 2017 Sep 25;10(3-4):91-107. doi: 10.1007/s12308-017-0302-2. eCollection 2017 Dec. Review.

6.

Pathways towards indolent B-cell lymphoma - Etiology and therapeutic strategies.

van den Brand M, Scheijen B, Hess CJ, van Krieken JHJ, Groenen PJTA.

Blood Rev. 2017 Nov;31(6):426-435. doi: 10.1016/j.blre.2017.08.002. Epub 2017 Aug 5. Review.

PMID:
28802906
7.

Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.

Katerndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Müschen M, Kornblau SM, Farrar MA.

Nat Immunol. 2017 Jun;18(6):694-704. doi: 10.1038/ni.3716. Epub 2017 Apr 3.

8.

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, van Emst L, van der Meer LT, Pieters R, Escherich G, Horstmann MA, Sonneveld E, Venn N, Sutton R, Dalla-Pozza L, Kuiper RP, Hoogerbrugge PM, den Boer ML, van Leeuwen FN.

Haematologica. 2017 Mar;102(3):541-551. doi: 10.3324/haematol.2016.153023. Epub 2016 Dec 15.

9.

Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.

Waanders E, Scheijen B, Jongmans MC, Venselaar H, van Reijmersdal SV, van Dijk AH, Pastorczak A, Weren RD, van der Schoot CE, van de Vorst M, Sonneveld E, Hoogerbrugge N, van der Velden VH, Gruhn B, Hoogerbrugge PM, van Dongen JJ, Geurts van Kessel A, van Leeuwen FN, Kuiper RP.

Leukemia. 2017 Apr;31(4):821-828. doi: 10.1038/leu.2016.277. Epub 2016 Oct 13.

PMID:
27733777
10.

Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development.

Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Havinga J, Rouault JP, Hoogerbrugge PM, van Leeuwen FN, Scheijen B.

Haematologica. 2016 Jul;101(7):e272-6. doi: 10.3324/haematol.2015.139675. Epub 2016 Apr 1. No abstract available.

11.

Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.

Marke R, Havinga J, Cloos J, Demkes M, Poelmans G, Yuniati L, van Ingen Schenau D, Sonneveld E, Waanders E, Pieters R, Kuiper RP, Hoogerbrugge PM, Kaspers GJ, van Leeuwen FN, Scheijen B.

Leukemia. 2016 Jul;30(7):1599-603. doi: 10.1038/leu.2015.359. Epub 2015 Dec 29. No abstract available.

PMID:
26713593
12.

Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress.

Yuniati L, van der Meer LT, Tijchon E, van Ingen Schenau D, van Emst L, Levers M, Palit SA, Rodenbach C, Poelmans G, Hoogerbrugge PM, Shan J, Kilberg MS, Scheijen B, van Leeuwen FN.

Oncotarget. 2016 Jan 19;7(3):3128-43. doi: 10.18632/oncotarget.6519.

13.

Altered cerebellum development and impaired motor coordination in mice lacking the Btg1 gene: Involvement of cyclin D1.

Ceccarelli M, Micheli L, D'Andrea G, De Bardi M, Scheijen B, Ciotti M, Leonardi L, Luvisetto S, Tirone F.

Dev Biol. 2015 Dec 1;408(1):109-25. doi: 10.1016/j.ydbio.2015.10.007. Epub 2015 Oct 31.

14.

Targeted Deletion of Btg1 and Btg2 Results in Homeotic Transformation of the Axial Skeleton.

Tijchon E, van Ingen Schenau D, van Opzeeland F, Tirone F, Hoogerbrugge PM, Van Leeuwen FN, Scheijen B.

PLoS One. 2015 Jul 28;10(7):e0131481. doi: 10.1371/journal.pone.0131481. eCollection 2015.

15.

DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia.

van der Sligte NE, Krumbholz M, Pastorczak A, Scheijen B, Tauer JT, Nowasz C, Sonneveld E, de Bock GH, Meeuwsen-de Boer TG, van Reijmersdal S, Kuiper RP, Bradtke J, Metzler M, Suttorp M, de Bont ES, van Leeuwen FN.

Br J Haematol. 2014 Jul;166(2):250-3. doi: 10.1111/bjh.12850. Epub 2014 Mar 27. Erratum in: Br J Haematol. 2014 Nov;167(4):584.

PMID:
24673583
16.

Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.

Lauc G, Huffman JE, Pučić M, Zgaga L, Adamczyk B, Mužinić A, Novokmet M, Polašek O, Gornik O, Krištić J, Keser T, Vitart V, Scheijen B, Uh HW, Molokhia M, Patrick AL, McKeigue P, Kolčić I, Lukić IK, Swann O, van Leeuwen FN, Ruhaak LR, Houwing-Duistermaat JJ, Slagboom PE, Beekman M, de Craen AJ, Deelder AM, Zeng Q, Wang W, Hastie ND, Gyllensten U, Wilson JF, Wuhrer M, Wright AF, Rudd PM, Hayward C, Aulchenko Y, Campbell H, Rudan I.

PLoS Genet. 2013;9(1):e1003225. doi: 10.1371/journal.pgen.1003225. Epub 2013 Jan 31.

17.

B-lineage transcription factors and cooperating gene lesions required for leukemia development.

Tijchon E, Havinga J, van Leeuwen FN, Scheijen B.

Leukemia. 2013 Mar;27(3):541-52. doi: 10.1038/leu.2012.293. Epub 2012 Oct 10. Review.

PMID:
23047478
18.

The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.

Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroeze Y, Sonneveld E, Hoogerbrugge PM, van Kessel AG, van Leeuwen FN, Kuiper RP.

PLoS Genet. 2012;8(2):e1002533. doi: 10.1371/journal.pgen.1002533. Epub 2012 Feb 16.

19.

Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response.

Wennemers M, Bussink J, Scheijen B, Nagtegaal ID, van Laarhoven HW, Raleigh JA, Varia MA, Heuvel JJ, Rouschop KM, Sweep FC, Span PN.

Breast Cancer Res. 2011 Aug 24;13(4):R82. doi: 10.1186/bcr2934.

20.

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van Dongen JJ, Veerman AJ, van Leeuwen FN, van Kessel AG, Hoogerbrugge PM.

Leukemia. 2010 Jul;24(7):1258-64. doi: 10.1038/leu.2010.87. Epub 2010 May 6.

PMID:
20445578
21.

BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia.

van Galen JC, Kuiper RP, van Emst L, Levers M, Tijchon E, Scheijen B, Waanders E, van Reijmersdal SV, Gilissen C, van Kessel AG, Hoogerbrugge PM, van Leeuwen FN.

Blood. 2010 Jun 10;115(23):4810-9. doi: 10.1182/blood-2009-05-223081. Epub 2010 Mar 30.

22.
23.

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.

Gu TL, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, Sternberg DW.

Blood. 2004 Jun 15;103(12):4622-9. Epub 2004 Feb 12.

24.

High incidence of thymic epithelial tumors in E2F2 transgenic mice.

Scheijen B, Bronk M, van der Meer T, De Jong D, Bernards R.

J Biol Chem. 2004 Mar 12;279(11):10476-83. Epub 2003 Dec 18.

25.

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD.

Adv Exp Med Biol. 2003;532:121-40. Review.

PMID:
12908554
26.

Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation.

Scheijen B, Bronk M, van der Meer T, Bernards R.

Mol Cell Biol. 2003 May;23(10):3656-68.

27.

Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease.

Scheijen B, Griffin JD.

Oncogene. 2002 May 13;21(21):3314-33. Review.

28.

Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.

Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M.

Genes Dev. 1999 Oct 15;13(20):2678-90.

29.

Identification and characterization of collaborating oncogenes in compound mutant mice.

Berns A, Mikkers H, Krimpenfort P, Allen J, Scheijen B, Jonkers J.

Cancer Res. 1999 Apr 1;59(7 Suppl):1773s-1777s.

PMID:
10197595
31.

Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging.

van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A.

Cell. 1991 May 31;65(5):737-52.

PMID:
1904008

Supplemental Content

Loading ...
Support Center